Elanco shifts focus to innovation and high-margin pet therapeutics amid transformation journey

Elanco Animal Health is repositioning from a mature brand consolidator to an innovation-driven player, emphasising pet therapeutics, biologics, and enabling technologies to boost growth and pricing power.

Elanco Animal Health is trying to redefine itself from a balance-sheet heavy consolidator of mature brands into a more innovation-led player in the higher-margin parts of animal health. That shift matters because the most attractive growth in the sector increasingly sits in pet therapeutics, biologics and technologies that can command pricing power rather than in commoditised products.

The company has been signalling that change for some time. Its innovation model now links research, manufacturing and quality teams more tightly, while Elanco says its global footprint spans 17 manufacturing sites and about 11,000 stock-keeping units. At its investor day in December 2025, it outlined a three-year plan centred on mid-single-digit organic constant-currency growth and roughly $1.1bn of innovation revenue contribution in 2026.

More recently, Elanco announced a $25m venture capital vehicle, Elanco Ventures, aimed at pre-seed to Series A companies working on animal-health therapeutics and enabling technologies. It also remains involved in BiomEdit, the microbiome-focused company it launched with Ginkgo Bioworks, which is targeting alternatives to antibiotics.

The strategy is still in execution rather than proof. But by pairing internal development with external capital and partnerships, Elanco is attempting to build a more durable growth platform.